## Nikki Parker

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11845745/publications.pdf

Version: 2024-02-01

687363 1058476 1,725 14 13 14 citations h-index g-index papers 14 14 14 2756 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Detecting Functional and Accessible Folate Receptor Expression in Cancer and Polycystic Kidneys. Molecular Pharmaceutics, 2019, 16, 3985-3995.	4.6	7
2	Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies. Frontiers in Oncology, 2019, 9, 151.	2.8	43
3	Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease. American Journal of Physiology - Renal Physiology, 2018, 315, F395-F405.	2.7	24
4	Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus. Molecular Medicine, 2015, 21, 584-596.	4.4	22
5	Targeting Folate Receptors to Treat Invasive Urinary Bladder Cancer. Cancer Research, 2013, 73, 875-884.	0.9	52
6	Reducing Undesirable Hepatic Clearance of a Tumor-Targeted Vinca Alkaloid via Novel Saccharopeptidic Modifications. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 336-343.	2.5	42
7	In Vivo Structural Activity and Optimization Studies of Folateâ^'Tubulysin Conjugates. Molecular Pharmaceutics, 2009, 6, 1518-1525.	4.6	60
8	Impact of High and Low Folate Diets on Tissue Folate Receptor Levels and Antitumor Responses Toward Folate-Drug Conjugates. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 918-925.	2.5	65
9	Folate Targeting Enables Durable and Specific Antitumor Responses from a Therapeutically Null Tubulysin B Analogue. Cancer Research, 2008, 68, 9839-9844.	0.9	86
10	Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. International Journal of Cancer, 2007, 121, 1585-1592.	5.1	77
11	Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate–targeted immunotherapy in hapten-immunized mice. Molecular Cancer Therapeutics, 2006, 5, 3258-3267.	4.1	33
12	Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Analytical Biochemistry, 2005, 338, 284-293.	2.4	1,054
13	Synthesis and Biological Evaluation of EC72:  A New Folate-Targeted Chemotherapeutic. Bioconjugate Chemistry, 2005, 16, 803-811.	3.6	78
14	Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. Journal of Nuclear Medicine, 2004, 45, 857-66.	5.0	82